Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.56 |
| ▸ | ALPG | P10696 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALPL | P05186 | 1/20 | 0.55 |
| ▸ | ALPI | P09923 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5069416 | 0.85 | MMP12 (0.64) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9260063 | 0.85 | CYP2C19 (0.71) | CYP2C19CYP1A2CYP2D6SMN1; SMN2LMNA | |
| SCHEMBL18392033 | 0.84 | ALDH1A1 (0.54) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10993407 | 0.84 | CYP2C19 (0.70) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL19514747 | 0.82 | CYP1A2 (0.69) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL333186 | 0.81 | FFAR1 (0.70) | LMNAALDH1A1FFAR1TDP1KEAP1 | |
| SCHEMBL30732385 | 0.80 | CYP1A2 (0.67) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL22922288 | 0.80 | CYP1A2 (0.67) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL8937697 | 0.79 | FFAR1 (0.68) | LMNAALDH1A1FFAR1TDP1KEAP1 | |
| SCHEMBL26111039 | 0.79 | FFAR1 (0.68) | LMNAALDH1A1FFAR1TDP1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | Akamara Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | Akamara Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20200199249-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | Akamara Therapeutics, Inc. (US) | 2020-06-25 | — | — | US | disclosed |
| US-10533059-B2 | Targeted drug delivery through affinity based linkers | Akamara Therapeutics, Inc. (US) | 2020-01-14 | — | — | US | disclosed |
| US-20170014528-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2017-01-19 | — | — | US | disclosed |
| US-20170014528-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2017-01-19 | — | — | US | disclosed |
| WO-2015148126-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2015-10-01 | — | — | WO | disclosed |
| US-8785499-B2 | Targeting NAD biosynthesis in bacterial pathogens | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785499-B2 | Targeting NAD biosynthesis in bacterial pathogens | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120190708-A1 | TARGETING NAD BIOSYNTHESIS IN BACTERIAL PATHOGENS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190708-A1 | TARGETING NAD BIOSYNTHESIS IN BACTERIAL PATHOGENS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014528-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | ABCG2, ADAM8, TIE1 | CYP2C19 1564/4885CYP1A2 2072/4885CYP3A4 884/4885 |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | ABCG2, FCGR2A, ABCB1 | CYP2C19 1680/4885CYP1A2 2069/4885CYP3A4 1428/4885 |
| US-20120190708-A1 | TARGETING NAD BIOSYNTHESIS IN BACTERIAL PATHOGENS | NAMPT, NAPRT, NADK | CYP2C19 2699/4885CYP1A2 2285/4885CYP3A4 1987/4885 |
| US-20200199249-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | ABCG2, FCGR2A, ABCB1 | CYP2C19 1680/4885CYP1A2 2069/4885CYP3A4 1428/4885 |
| US-10533059-B2 | Targeted drug delivery through affinity based linkers | ABCG2, ADAM8, TIE1 | CYP2C19 1564/4885CYP1A2 2072/4885CYP3A4 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.